Summary | |
---|---|
Symbol | FHL5 |
Name | four and a half LIM domains 5 |
Aliases | FLJ33049; dJ393D12.2; 1700027G07Rik; FHL-5; LIM protein ACT; activator of CREM in testis; activator of cAMP- ...... |
Chromosomal Location | 6q16.1-q16.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus Note=Nuclei of round and elongated spermatids. |
Domain |
PF00412 LIM domain |
Function |
May be involved in the regulation of spermatogenesis. Stimulates CREM transcriptional activity in a phosphorylation-independent manner. |
Biological Process | - |
Molecular Function |
GO:0003713 transcription coactivator activity |
Cellular Component | - |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | FHL5 |
Name | four and a half LIM domains 5 |
Aliases | FLJ33049; dJ393D12.2; 1700027G07Rik; FHL-5; LIM protein ACT; activator of CREM in testis; activator of cAMP- ...... |
Chromosomal Location | 6q16.1-q16.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between FHL5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | FHL5 |
Name | four and a half LIM domains 5 |
Aliases | FLJ33049; dJ393D12.2; 1700027G07Rik; FHL-5; LIM protein ACT; activator of CREM in testis; activator of cAMP- ...... |
Chromosomal Location | 6q16.1-q16.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of FHL5 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | FHL5 |
Name | four and a half LIM domains 5 |
Aliases | FLJ33049; dJ393D12.2; 1700027G07Rik; FHL-5; LIM protein ACT; activator of CREM in testis; activator of cAMP- ...... |
Chromosomal Location | 6q16.1-q16.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of FHL5 in various data sets.
|
Points in the above scatter plot represent the mutation difference of FHL5 in various data sets.
|
Summary | |
---|---|
Symbol | FHL5 |
Name | four and a half LIM domains 5 |
Aliases | FLJ33049; dJ393D12.2; 1700027G07Rik; FHL-5; LIM protein ACT; activator of CREM in testis; activator of cAMP- ...... |
Chromosomal Location | 6q16.1-q16.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FHL5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | FHL5 |
Name | four and a half LIM domains 5 |
Aliases | FLJ33049; dJ393D12.2; 1700027G07Rik; FHL-5; LIM protein ACT; activator of CREM in testis; activator of cAMP- ...... |
Chromosomal Location | 6q16.1-q16.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FHL5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FHL5. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | FHL5 |
Name | four and a half LIM domains 5 |
Aliases | FLJ33049; dJ393D12.2; 1700027G07Rik; FHL-5; LIM protein ACT; activator of CREM in testis; activator of cAMP- ...... |
Chromosomal Location | 6q16.1-q16.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FHL5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | FHL5 |
Name | four and a half LIM domains 5 |
Aliases | FLJ33049; dJ393D12.2; 1700027G07Rik; FHL-5; LIM protein ACT; activator of CREM in testis; activator of cAMP- ...... |
Chromosomal Location | 6q16.1-q16.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of FHL5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | FHL5 |
Name | four and a half LIM domains 5 |
Aliases | FLJ33049; dJ393D12.2; 1700027G07Rik; FHL-5; LIM protein ACT; activator of CREM in testis; activator of cAMP- ...... |
Chromosomal Location | 6q16.1-q16.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between FHL5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | FHL5 |
Name | four and a half LIM domains 5 |
Aliases | FLJ33049; dJ393D12.2; 1700027G07Rik; FHL-5; LIM protein ACT; activator of CREM in testis; activator of cAMP- ...... |
Chromosomal Location | 6q16.1-q16.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting FHL5 collected from DrugBank database. |
There is no record. |